Plunkett Research Online: Editas Medicine Inc

EDITAS MEDICINE INC (EDIT:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Editas Medicine, Inc. is a genome editing company dedicated to treating patients with genetically-define disease by correcting their disease-causing genes. The firm’s CRISPR (clustered, regularly interspaced short palindromic repeats)/Cas9 (CRISPR associated protein 9) technology has the potential .....



Editas Medicine Inc
Ticker: EDIT
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 617-401-9000
Fax:
Address: 11 Hurley Street
Cambridge, MA 02141 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Biological Product (except Diagnostic) Manufacturing
ContactsDescription
Andrew HackCFO/Chief Accounting Officer
Gerald CoxChief Medical Officer
See More
Editas Medicine, Inc. is a genome editing company dedicated to treating patients with genetically-define disease by correcting their disease-causing genes. The firm’s CRISPR (clustered, regularly interspaced short palindromic repeats)/Cas9 (CRISPR associated protein 9) technology has the potential .....See More See More

Auditor: Ernst & Young LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201620152014
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
CRISPR
Cas9
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: